+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-06-01Number of Pages: 232

Companion Diagnostic Tests in Oncology Market (Detection Technique - Protein Detection, DNA Detection (Polymerase Chain Reaction, Next Generation Sequencing, and In Situ Hybridization (Fluorescence In Situ Hybridization, and Chromogenic In Situ Hybridization)); Biomarker - EGFR, BRAF V600E, KRAS, and HER2; Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Liver Cancer, and Melanoma; End User - Pharmaceutical and Biotechnology Companies, Medical Device Companies, and Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

Global Companion Diagnostic Tests in Oncology Market: Snapshot

The global companion diagnostic tests in oncology market is expected to register phenomenal pace owing to increasing adoption of new tests, and rising shift from blockbuster drugs to personalized medicines, and targeted therapies. Increasing incidence of cancer, rising cost burden of cancer treatment, and increasing mortalities due to cancer, are some of the major reasons for increasing demand for new and technologically advanced treatment options, therapies, and drugs for the treatment of cancer. Increasing focus on research and development by various pharmaceutical and biotechnology companies, along with medical device companies, and increasing funding and grants for cancer research by various government agencies have led to high adoption of companion diagnostic tests in oncology.  According to the research report, the global companion diagnostic tests in oncology market is expected to be worth US$13.6 bn by the end of 2025 from US$3.5 bn in 2016. During the forecast period of 2017 and 2025, the global market is projected to rise at a CAGR of 16.8%.

 

companion-diagnostic-tests-in-oncology-market

 

EGFR Biomarker to Remain Popular Amongst Pharmaceutical Companies

Among the biomarker segment, the EGFR biomarker segment accounted for the largest share of the global companion diagnostic tests in oncology market in 2016. It is expected to register highest CAGR during the forecast period of 2017-2025, owing to major factors such as increasing incidence of lung cancer, and rising R&D in biomarker segment. The HER2 and KRAS biomarkers are expected to register high CAGR during the forecast period, due to increasing incidence of cancer, and rising adoption of biomarker by pharmaceutical companies and research institutes. Analysts expect that the EGFR biomarker segment will register a CAGR of 18.4% over the forecast period.

Among the cancer types segment, the breast cancer segment accounted for the largest share of the global companion diagnostic tests in oncology market in 2016. However lung cancer segment is expected to register highest CAGR during the forecast period of 2017-2025, owing to increasing incidence of lung cancer in developing countries. This shift is attributable to the increased smoking and rising biomarker research for the lung cancer treatment. According to statistics from the World Health Organization (WHO), in 2013, an estimated 1.9 million new cases of lung cancer were diagnosed, and the stats reveled that less developed regions including the emerging countries such as China, India, and other countries, had the highest incidence of lung cancer, owing to rising smoking habits and poor air quality in these countries.

 

North America to Remain Dominant with Higher Acceptance of Technologies

Geographically, the global companion diagnostic tests in oncology market is segmented into North America, the Middle East and Africa, Asia Pacific, Europe, and Latin America. Analysts expect that North America will continue to dominate the global market due to the higher acceptance of technology in the region. Furthermore, better rate of diagnoses in the region is also likely to favor the regional market’s growth. By the end of 2025, the regional market is projected to account for a share of 37.5% in the global market. On the other hand, Asia Pacific is also expected to offer lucrative opportunities due to high rate of unmet medical needs in the emerging economies of the region.

Major players having presence in the global companion diagnostic tests in oncology market include F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher Scientific, Inc., among others.   

1. Preface                
     1.1. Market Definition and Scope                
     1.2. Market Segmentation                
     1.3. Key Research Objectives                
     1.4. Research Highlights                

2. Assumptions and Research Methodology                

3. Executive Summary : Global Digital Companion Diagnostics Market                

4. Market Overview                
     4.1. Introduction                
            4.1.1 Detection Technique Definition                
            4.1.2 Industry Evolution / Developments                
     4.2. Overview                
     4.3. Key Market Indicators                
     4.4. Market Dynamics                
            4.4.1 Drivers                
            4.4.2 Restraints                
            4.4.3 Opportunity                
     4.5. Global Digital Companion Diagnostics Market  Analysis and Forecasts, 2015–2025                
            4.5.1 Market Revenue Projections (US$ Mn)                
     4.6. Porter’s Five Force Analysis                
     4.7. Market Outlook                
     4.8. Future Trends: response-guided therapy, theranostic                
     4.9. FDA breakthrough therapies: For Companion Diagnostic Tests                
     4.10. Overview FDA approved in-vitro Companion Diagnostic Tests                
     4.11. Companion Diagnostics and regulatory requirements : region  wise                
     4.12. Companion Diagnostic Tests - Intended Diagnostics Type - Market Players     
     4.13. Pipeline Overview: Major market players                

5. Global Digital Companion Diagnostics Market  Analysis and Forecasts, By Detection Technique                 
     5.1. Introduction & Definition                
     5.2. Key Findings / Developments                
     5.3. Key Trends                
     5.4. Market Value Forecast By Detection Technique , 2015–2025                
            5.4.1 Protein Detection                
                     5.4.1.1 Immunohistochemistry                
            5.4.2 DNA Detection                
                     5.4.2.1 Polymerase Chain Reaction                
                     5.4.2.2 Next Gen Sequencing                
                     5.4.2.3 In-Situ Hybridization                
            5.4.3 Others                
     5.5. Market Attractiveness By Detection Technique                 

6. Global Digital Companion Diagnostics Market Analysis and Forecasts, By Bio-markers                 
     6.1. Introduction & Definition                
     6.2. Key Findings / Developments                
     6.3. Key Trends                     
     6.4. Market Value Forecast By Bio-markers, 2015–2025                
            6.4.1. EGFR                
            6.4.2. KRAS                
            6.4.3. BRAF V600E                
            6.4.4. HER2                
            6.4.5. Others                
     6.5. Market Attractiveness By Bio-markers                 

7. Global Digital Companion Diagnostics Market  Analysis and Forecasts, By Cancer Type                 
     7.1. Introduction & Definition                
     7.2. Key Findings / Developments                
     7.3. Key Trends                
     7.4. Market Value Forecast By Cancer Type , 2015–2025                
            7.4.1 Breast Cancer                
            7.4.2 Liver Cancer                
            7.4.3 Lung Cancer                
            7.4.4 Colorectal Cancer                
            7.4.5 Melanoma                
            7.4.6 Others                 
     7.5. Market Attractiveness By Cancer Type                 

8. Global Digital Companion Diagnostics Market  Analysis and Forecasts, By End User 
     8.1. Introduction & Definition                
     8.2. Key Findings / Developments                
     8.3. Key Trends                
     8.4. Market Value Forecast By End User , 2015–2025                
            8.4.1 Hospitals                
            8.4.2 Specialty Clinics                
            8.4.3 Diagnostic Labs                
            8.4.4 Others                
     8.5. Market Attractiveness By End User                 

9. Global Digital Companion Diagnostics Market  Analysis and Forecasts, By Region   
     9.1. Key Findings                
     9.2. Policies and Regulations                
     9.3. Market Value Forecast By Region                
            9.3.1 North America                 
            9.3.2 Europe                 
            9.3.3 Asia Pacific                 
            9.3.4 Latin America                 
            9.3.5 Middle East and Africa                 
     9.4. Market Attractiveness By Country/Region                

10. North America Digital Companion Diagnostics Market  Analysis and Forecast       
     10.1. Introduction                
            10.1.1 Key Findings                
            10.1.2 Policies and Regulations                
            10.1.3 Key Trends                
     10.2. Market Value Forecast By Detection Technique, 2015–2025                
            10.2.1 Protein Detection                
                     10.2.1.1 Immunohistochemistry                
            10.2.2 DNA Detection                
                     10.2.2.1 Polymerase Chain Reaction                
                     10.2.2.2 Next Gen Sequencing                
                     10.2.2.3 In-Situ Hybridization                
            10.2.3 Others                
     10.3. Market Value Forecast By Bio-markers, 2015–2025                
            10.3.1 EGFR                
            10.3.2 KRAS                
            10.3.3 BRAF V600E                
            10.3.4 HER2                
            10.3.5 Others                
     10.4. Market Value Forecast By Cancer Type , 2015–2025                
            10.4.1 Breast Cancer                
            10.4.2 Liver Cancer                
            10.4.3 Lung Cancer                
            10.4.4 Colorectal Cancer                
            10.4.5 Melanoma                
            10.4.6 Others                 
     10.5. Market Value Forecast By End User , 2015–2025                
            10.5.1 Hospitals                
            10.5.2 Specialty Clinics                
            10.5.3 Diagnostic Labs                
            10.5.4 Others                
     10.6. Market Value Forecast By Country , 2015–2025                
            10.6.1 U.S.                
            10.6.2 Canada                
     10.6. Market Attractiveness Analysis                 
            10.6.1 By Detection Technique                 
            10.6.2 By Bio-markers                 
            10.6.3 By Cancer Type                 
            10.6.4 By End User                 
            10.6.5 By Country                

11. Europe Digital Companion Diagnostics Market  Analysis and Forecast                11.1. Introduction                
            11.1.1 Key Findings                
            11.1.2 Policies and Regulations                
            11.1.3 Key Trends                
     11.2. Market Value Forecast By Detection Technique , 2015–2025                
            11.2.1 Protein Detection                
                     11.2.1.1 Immunohistochemistry                
            11.2.2 DNA Detection                
                     11.2.2.1 Polymerase Chain Reaction                
                     11.2.2.2 Next Gen Sequencing                
                     11.2.2.3 In-Situ Hybridization                
            11.2.3. Others                
     11.3. Market Value Forecast By Bio-markers , 2015–2025                
            11.3.1 EGFR                
            11.3.2 KRAS                
            11.3.3 BRAF V600E                
            11.3.4 HER2                
            11.3.5 Others                
     11.4. Market Value Forecast By Cancer Type , 2015–2025                
            11.4.1 Breast Cancer                
            11.4.2 Liver Cancer                
            11.4.3 Lung Cancer                
            11.4.4 Colorectal Cancer                
            11.4.5 Melanoma                
            11.4.6 Others                 
     11.5. Market Value Forecast By End User , 2015–2025                
            11.5.1 Hospitals                
            11.5.2 Specialty Clinics                
            11.5.3 Diagnostic Labs                
            11.5.4 Others                
     11.6. Market Value Forecast By Country , 2015–2025                
            11.6.1 U.K.                
            11.6.2 Germany                
            11.6.3 France                
            11.6.4 Italy                
            11.6.5 Spain                
            11.6.6 Russia                
            11.6.7 Rest of Europe                
     11.7. Market Attractiveness Analysis                 
            11.7.1 By Detection Technique                 
            11.7.2 By Bio-markers                 
            11.7.3 By Cancer Type                 
            11.7.4 By End User                 
            11.7.5 By Country                

12. Asia Pacific Digital Companion Diagnostics Market  Analysis and Forecast        12.1. Introduction                
            12.1.1 Key Findings                
            12.1.2 Policies and Regulations                
            12.1.3 Key Trends                
     12.2. Market Value Forecast By Detection Technique , 2015–2025                
            12.2.1 Protein Detection                
                     12.2.1.1 Immunohistochemistry                
            12.2.2 DNA Detection                
                     12.2.2.1 Polymerase Chain Reaction                
                     12.2.2.2 Next Gen Sequencing                
                     12.2.2.3 In-Situ Hybridization                
            12.2.3 Others                
     12.3. Market Value Forecast By Bio-markers , 2015–2025                
            12.3.1 EGFR                
            12.3.2 KRAS                
            12.3.3 BRAF V600E                
            12.3.4 HER2                
            12.3.5 Others                
     12.4. Market Value Forecast By Cancer Type , 2015–2025                
            12.4.1 Breast Cancer                
            12.4.2 Liver Cancer                
            12.4.3 Lung Cancer                
            12.4.4 Colorectal Cancer                
            12.4.5 Melanoma                
            12.4.6 Others                 
     12.5. Market Value Forecast By End User , 2015–2025                
            12.5.1 Hospitals                
            12.5.2 Specialty Clinics                
            12.5.3 Diagnostic Labs                
            12.5.4 Others                
     12.6. Market Value Forecast By Country , 2015–2025                
            12.6.1 India                
            12.6.2 China                
            12.6.3 Japan                
            12.6.4 Australia & New Zealand                
            12.6.5 Rest of Asia Pacific                
     12.7. Market Attractiveness Analysis                 
            12.7.1 By Detection Technique                 
            12.7.2 By Bio-markers                 
            12.7.3 By Cancer Type                 
            12.7.4 By End User                 
            12.7.5 By Country                

13. Latin America Digital Companion Diagnostics Market  Analysis and Forecast                
     13.1. Introduction                
            13.1.1 Key Findings                
            13.1.2 Policies and Regulations                
            13.1.4 Key Trends                
     13.2. Market Value Forecast By Detection Technique , 2015–2025                
            13.2.1 Protein Detection                
                     13.2.1.1 Immunohistochemistry                
            13.2.2 DNA Detection                
                     13.2.2.1 Polymerase Chain Reaction                
                     13.2.2.2 Next Gen Sequencing                
                     13.2.2.3 In-Situ Hybridization                
            13.2.3 Others                
     13.3. Market Value Forecast By Bio-markers , 2015–2025                
            13.3.1 EGFR                
            13.3.2 KRAS                
            13.3.3 BRAF V600E                
            13.3.4 HER2                
            13.3.5 Others                
     13.4. Market Value Forecast By Cancer Type , 2015–2025                
            13.4.1 Breast Cancer                
            13.4.2 Liver Cancer                
            13.4.3 Lung Cancer                
            13.4.4 Colorectal Cancer                
            13.4.5 Melanoma                
            13.4.6 Others                 
     13.5. Market Value Forecast By End User , 2015–2025                
            13.5.1 Hospitals                
            13.5.2 Specialty Clinics                
            13.5.3 Diagnostic Labs                
            13.5.4. Others                
     13.6. Market Value Forecast By Country , 2015–2025                
            13.6.1 Brazil                
            13.6.2 Mexico                
            13.6.3 Rest of Latin America                
     13.7. Market Attractiveness Analysis                 
            13.7.1 By Detection Technique                 
            13.7.2 By Bio-markers                 
            13.7.3 By Cancer Type                 
            13.7.4 By End User                 
            13.7.5 By Country                

14. Middle East and Africa Digital Companion Diagnostics Market  Analysis and Forecast                
     14.1. Introduction                
            14.1.1 Key Findings                
            14.1.2 Policies and Regulations                
            14.1.4 Key Trends                
     14.2. Market Value Forecast By Detection Technique , 2015–2025                
            14.2.1 Protein Detection                
                     14.2.1.1 Immunohistochemistry                
            14.2.2 DNA Detection                
                     14.2.2.1 Polymerase Chain Reaction                
                     14.2.2.2 Next Gen Sequencing                
                     14.2.2.3 In-Situ Hybridization                
            14.2.3 Others                
     14.3. Market Value Forecast By Bio-markers , 2015–2025                
            14.3.1 EGFR                
            14.3.2 KRAS                
            14.3.3 BRAF V600E                
            14.3.4 HER2                
            14.3.5 Others                
     14.4. Market Value Forecast By Cancer Type , 2015–2025                
            14.4.1 Breast Cancer                
            14.4.2 Liver Cancer                
            14.4.3 Lung Cancer                
            14.4.4 Colorectal Cancer                
            14.4.5 Melanoma                
            14.4.6 Others                 
     14.5. Market Value Forecast By End User , 2015–2025                
            14.5.1 Hospitals                
            14.5.2 Specialty Clinics                
            14.5.3 Diagnostic Labs                
            14.5.4 Others                
     14.6. Market Value Forecast By Country , 2015–2025                
            14.6.1 South Africa                
            14.6.2 GCC Countries                
            14.6.3 Rest of Middle East and Africa                
     14.7. Market Attractiveness Analysis                 
            14.7.1 By Detection Technique                 
            14.7.2 By Bio-markers                 
            14.7.4 By Cancer Type                 
            14.7.5 By End User                 
            14.7.6 By Country                

15. Competition Landscape
     15.1 Market Player – Competition Matrix (By Tier and Size of companies)
     15.2 Market Share Analysis By Company (2015)
     15.3 Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            15.3.1 Abbott
                     15.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.1.2 Financial Overview
                     15.3.1.3 Product Portfolio
                     15.3.1.4 SWOT Analysis
                     15.3.1.5 Strategic Overview
            15.3.2 F. Hoffman LA Roche Ltd. 
                     15.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.2.2 Financial Overview
                     15.3.2.3 Product Portfolio
                     15.3.2.4 SWOT Analysis
                     15.3.2.5 Strategic Overview
            15.3.3 Genomic Health, Inc.
                     15.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.3.2 Financial Overview
                     15.3.3.3 Product Portfolio
                     15.3.3.4 SWOT Analysis
                     15.3.3.5 Strategic Overview
            15.3.4 QIAGEN
                     15.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.4.2 Financial Overview
                     15.3.4.3 Product Portfolio
                     15.3.4.4 SWOT Analysis
                     15.3.4.5 Strategic Overview
            15.3.5 Agilent Technologies, Inc.
                     15.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.5.2 Financial Overview
                     15.3.5.3 Product Portfolio
                     15.3.5.4 SWOT Analysis
                     15.3.5.5 Strategic Overview
            15.3.6 AGENDIA NV
                     15.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.6.2 Financial Overview
                     15.3.6.3 Product Portfolio
                     15.3.6.4 SWOT Analysis
                     15.3.6.5 Strategic Overview
            15.3.7 bioMerieux SA
                     15.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.7.2 Financial Overview
                     15.3.7.3 Product Portfolio
                     15.3.7.4 SWOT Analysis
                     15.3.7.5 Strategic Overview
            15.3.8 Illumina, Inc.
                     15.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.8.2 Financial Overview
                     15.3.8.3 Product Portfolio
                     15.3.8.4 SWOT Analysis
                     15.3.8.5 Strategic Overview
            15.3.9 Siemens Healthcare GmBH
                     15.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.9.2 Financial Overview
                     15.3.9.3 Product Portfolio
                     15.3.9.4 SWOT Analysis
                     15.3.9.5 Strategic Overview
            15.3.10 Thermo Fisher Scientific, Inc.
                     15.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.10.2 Financial Overview
                     15.3.10.3 Product Portfolio
                     15.3.10.4 SWOT Analysis
                     15.3.10.5 Strategic Overview
            15.3.11 BioGenex
                     15.3.11.1 Company Overview (HQ, Business Segments, Employee Strengths)
                     15.3.11.2 Financial Overview
                     15.3.11.3 Product Portfolio
                     15.3.11.4 SWOT Analysis
                     15.3.11.5 Strategic Overview

List of Figures

Figure 01: Global Companion Diagnostic Tests in Oncology, Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type (2016)
Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker (2016)
Figure 04: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique (2016)
Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region (2016)
Figure 06: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user (2016)
Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 08: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 09: Global Protein Detection Technique in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 10: Global DNA Detection Technique in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 11: Global Other Detection Techniques in Companion Diagnostic Tests, Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 14: Global Companion Diagnostic Tests in Oncology Market, by EGFR Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 15: Global Companion Diagnostic Tests in Oncology Market, by KRAS Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 16: Global Companion Diagnostic Tests in Oncology Market, by BRAF V600E Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 17: Global Companion Diagnostic Tests in Oncology Market, by HER2 Biomarker, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 18: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 19: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 20: Global Companion Diagnostic Tests in Oncology Market, by Breast Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 21: Global Companion Diagnostic Tests in Oncology Market, by Lung Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 22: Global Companion Diagnostic Tests in Oncology Market, by Liver Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 23: Global Companion Diagnostic Tests in Oncology Market, by Colorectal Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 24: Global Companion Diagnostic Tests in Oncology Market, by Melanoma Cancer, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 25: Global Companion Diagnostic Tests in Oncology Market, by Other Cancers, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2015–2025
Figure 26: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 27: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 28: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Pharmaceutical & Biotechnology Companies, 2015–2025
Figure 29: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Medical Device Companies, 2015–2025
Figure 30: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Research Laboratories, 2015–2025
Figure 31: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Others, 2015–2025
Figure 32: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2017 and 2025 
Figure 33: Global Companion Diagnostic Tests in Oncology Market Attractiveness, by Region, 2017–2025
Figure 34: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
Figure 35: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2017 and 2025
Figure 36: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 37: North America Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 38: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 39: North America Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 40: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 41: North America Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 42: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 43: North America Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 44: North America Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 45: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 46: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025 
Figure 47: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 48: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 49: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 50: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 51: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 52: Europe Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 53: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 54: Europe Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 55: Europe Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 56: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 57: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025 
Figure 58: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 59: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 60: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 61: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 62: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 63: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 64: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 65: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 66: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 67: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
Figure 68: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Country, 2017 and 2025 
Figure 69: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Country, 2017–2025
Figure 70: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2017 and 2025
Figure 71: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Detection Technique, 2017–2025
Figure 72: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 73: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 74: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2017 and 2025
Figure 75: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by Cancer Type, 2017–2025
Figure 76: Latin America Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2017 and 2025
Figure 77: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness, by End-user, 2017–2025
Figure 78: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 79: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2017 and 2025 
Figure 80: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2017–2025
Figure 81: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2017 and 2025
Figure 82: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2017–2025
Figure 83: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2017 and 2025
Figure 84: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness, by Biomarker, 2017–2025
Figure 85: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2017 and 2025
Figure 86: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2017–2025
Figure 87: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2017 and 2025
Figure 88: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2017–2025
Figure 89: Global Companion Diagnostic Tests in Oncology Market Share, by Company, 2016

List of Tables

Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 06: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 07: Global Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 09: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 11: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 12: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 13: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 14: North America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 16: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 17: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 18: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 19: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 20: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 21: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 22: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 23: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique,
Table 24: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 25: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 26: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 27: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 28: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 29: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 30: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 31: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 32: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 33: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 34: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 35: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025
Table 36: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 37: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Detection Technique, 2015–2025
Table 38: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by DNA Detection Technique, 2015–2025
Table 39: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by In Situ Hybridization DNA Detection Technique, 2015–2025
Table 40: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Biomarker, 2015–2025
Table 41: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 42: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Mn) Forecast, by End-user, 2015–2025

Global Companion Diagnostic Tests in Oncology Market: Overview

Companion diagnostics (CDx) are the tests or assays intended to assist physicians in making effective treatment decisions based on the patient response to the ongoing treatment with a targeted therapeutic area. These tests are an indicative measure of the patient sub-population that will be benefitted from the suggested drug / therapy, and differentiates the non-responder patients from the one’s who will respond to the treatment option. Hence, these diagnostic tests ensure the commercialization of safer and efficient targeted therapeutics with minimal or no side effects, while ensuring economic benefits to pharmaceutical companies, and the patients as well. Of late, many leading pharmaceutical companies are focusing on regulating the costs incurred in the drug discovery, development and commercialization process. This effort involves the development of companion diagnostic along with a targeted therapeutic area, and this has led to increasing collaborations between pharmaceutical and medical device companies, to co-develop a drug with companion diagnostic test. The tremendous research in the field of oncology, has led to the discovery of numerous biomarkers facilitating disease diagnosis and treatment, and these are some major factors contributing to the increasing demand for personalized medicine, and companion diagnostics tests in oncology.

The market overview section of the report comprises qualitative analysis of the overall companion diagnostic tests in oncology market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, market opportunity analysis for detection techniques, biomarker, and type of cancer, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics.

Global Companion Diagnostic Tests in Oncology Market: Segmentation

The global companion diagnostic tests in oncology market has been segmented on the basis of detection technique, biomarker, cancer type, and end-user. On the basis of detection technique, the global companion diagnostic tests in oncology market is segmented into protein detection technique, DNA detection technique, and other detection techniques.  The DNA detection techniques are further segmented into polymerase chain reaction, next generation sequencing, and in situ hybridization detection techniques. The biomarker segment of the global companion diagnostic tests in oncology market is segmented into EGFR, HER2, KRAS, BRAF V600E, and other biomarkers. The cancer type segment of the global companion diagnostic tests in oncology market is further segmented into breast cancer, lung cancer, liver cancer, melanoma, colorectal cancer, and other cancers. The end-user segment includes pharmaceutical & biotechnology companies, medical device companies, research institutes, and other end-users. The market for these detection techniques, biomarker, cancer types and end users has been extensively analyzed on the basis of factors such as incidence, prevalence of diseases, usage pattern of detection techniques, sales revenue of the tests, geographic presence of the market players and technological developments. The market size and forecast in terms of revenue (US$ Mn) for each of these segments have been provided for the period 2015 to 2025, considering 2016 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2017 to 2025.

Global Companion Diagnostic Tests in Oncology Market: Regional Outlook

Geographically, the companion diagnostic tests in oncology market has been segmented into five regions namely; North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2015 to 2025, in terms of detection techniques, biomarker, cancer type, and end-user along with the CAGR (%) for the forecast period 2017-2025.

Global Companion Diagnostic Tests in Oncology Market: Competitive Landscape

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global companion diagnostic tests in oncology market, in terms of percentage share in 2016 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the global Companion Diagnostic Tests in Oncology market such as F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher Scientific, Inc., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

The global companion diagnostic tests in oncology market is segmented as follows:

  • Global Companion Diagnostic Tests in Oncology Market, By Detection Technique
    • Protein Detection
    • DNA Detection
      • Polymerase Chain Reaction (PCR)
      • Next Gen Sequencing (NGS)
      • In Situ Hybridization
        • Fluorescence In Situ Hybridization (FISH)
        • Chromogenic In Situ Hybridization (CISH)
    • Others
       
  • Global Companion Diagnostic Tests in Oncology Market, by Biomarker
    • EGFR
    • KRAS
    • HER2
    • BRAF V600E
    • Others
  • Global Companion Diagnostic Tests in Oncology Market, by Cancer Type
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Melanoma
    • Others
       
  • Global Companion Diagnostic Tests in Oncology Market, by End Users
    • Pharmaceutical & Biotechnology Companies
    • Medical Device Companies
    • Research Institutes
    • Others
       
  • Global Companion Diagnostic Tests in Oncology Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East & Africa


 
 
Back To Top